![Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use | Fierce Pharma Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1576589763/Nubeqa.jpg/Nubeqa.jpg?VersionId=zQBkw4Bvd84364vsFYed4zv59Csd6Zk5)
Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use | Fierce Pharma
![Breakthrough triple treatment for prostate cancer offers patients years more healthy life | Daily Mail Online Breakthrough triple treatment for prostate cancer offers patients years more healthy life | Daily Mail Online](https://i.dailymail.co.uk/1s/2022/02/26/16/54688177-0-image-a-7_1645894363858.jpg)
Breakthrough triple treatment for prostate cancer offers patients years more healthy life | Daily Mail Online
![Abiraterone keeps men with prostate cancer at risk of spreading alive for longer - The Institute of Cancer Research, London Abiraterone keeps men with prostate cancer at risk of spreading alive for longer - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/images/default-source/default-album/white-abiraterone-pill-16-9040834cb659564f3a772ff0000325351.jpg?sfvrsn=75925069_2)
Abiraterone keeps men with prostate cancer at risk of spreading alive for longer - The Institute of Cancer Research, London
![Bicalutamide antiandrogen pack of tablets hormone medical treatment for prostate cancer Stock Photo - Alamy Bicalutamide antiandrogen pack of tablets hormone medical treatment for prostate cancer Stock Photo - Alamy](https://c8.alamy.com/comp/2BAJXAP/bicalutamide-antiandrogen-pack-of-tablets-hormone-medical-treatment-for-prostate-cancer-2BAJXAP.jpg)
Bicalutamide antiandrogen pack of tablets hormone medical treatment for prostate cancer Stock Photo - Alamy
![Abiraterone could halve risk of prostate cancer death for some patients - The Institute of Cancer Research, London Abiraterone could halve risk of prostate cancer death for some patients - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/default-album/abiraterone.jpg?sfvrsn=46096f69_4)